Besides the downregulation of FMRP, we show that both MIA and the FXS conditions lead to the hyperactivation of mTOR, as previously described [25, 34, 71, 101] and potentially increased rate of translation through the dysregulation of distinct components of the mTOR signaling pathway. The gene discussed is MTOR; the disease is fragile X syndrome.